<p>Hims
&amp; Hers Health (NYSE:HIMS - 獲取免費報告) 在週二發佈給投資者的研究報告中，銀行美林的股票分析師將其目標價格從 21.00 美元上調至 22.00 美元。該公司目前對該股票的評級為 “表現不佳”。銀行美林的目標價格意味着該公司當前價格可能下跌 36.56%。</p>
<p>獲取 <strong>Hims
&amp; Hers Health</strong> 的提醒：</p>
<ul>
<li>Viking Therapeutics 是下一個熱門的 GLP-1 股票嗎？</li>
</ul>
<p>其他一些股票研究分析師最近也對 HIMS 發佈了報告。Truist Financial 將 Hims
&amp; Hers Health 的目標價格從 24.00 美元上調至 39.00 美元，並在 2 月 26 日的研究報告中給予該公司 “持有” 評級。Leerink Partners 將 Hims
&amp; Hers Health 的目標價格從 24.00 美元上調至 40.00 美元，並在 2 月 25 日的研究報告中給予該公司 “市場表現” 評級。Needham
&amp; Company LLC 將 Hims
&amp; Hers Health 的目標價格從 31.00 美元上調至 61.00 美元，並在 2 月 25 日的研究報告中給予該股票 “買入” 評級。花旗集團在 3 月 6 日的報告中重申了 “賣出” 評級，並對 Hims
&amp; Hers Health 的股票設定了 27.00 美元的目標價格。最後，Canaccord Genuity Group 將 Hims
&amp; Hers Health 的目標價格從 38.00 美元上調至 68.00 美元，並在 2 月 19 日的報告中給予該股票 “買入” 評級。兩位股票研究分析師對該股票給予了賣出評級，七位給予了持有評級，六位給予了買入評級。根據 MarketBeat 的數據，該股票的共識評級為 “持有”，平均目標價格為 37.31 美元。</p>
<p>** 查看我們最新的 Hims
&amp; Hers Health 股票報告 **</p>
<h2>Hims</h2>
<p>&amp; Hers Health 股票上漲 4.6%</p>
<ul>
<li>儘管面臨挑戰，諾和諾德計劃擊敗 GLP-1 競爭對手</li>
</ul>
<p>HIMS 週二開盤價為 34.68 美元。該公司的 50 日移動平均價格為 38.64 美元，200 日移動平均價格為 28.37 美元。Hims
&amp; Hers Health 的 52 周低點為 11.20 美元，52 周高點為 72.98 美元。該公司的市值為 77 億美元，市盈率為 78.82，貝塔值為 1.37。</p>
<p>Hims
&amp; Hers Health (NYSE:HIMS - 獲取免費報告) 最近在 2 月 24 日發佈了季度財報。該公司報告每股收益（EPS）為 0.11 美元，超出分析師共識預期的 0.09 美元，超出幅度為 0.02 美元。Hims
&amp; Hers Health 的淨利潤率為 8.19%，股本回報率為 10.97%。該公司本季度的收入為 4.8114 億美元，而分析師預期為 4.9456 億美元。整體來看，賣方分析師預計 Hims
&amp; Hers Health 本財年的每股收益將為 0.29 美元。</p>
<h2>Hims</h2>
<p>&amp; Hers Health 的內部交易</p>
<ul>
<li>MarketBeat 週迴顧 – 03/03 - 03/07</li>
</ul>
<p>在相關消息中，內部人士 Soleil Boughton 於 1 月 6 日以交易方式出售了 268,932 股該股票。該股票的平均售價為 27.75 美元，總價值為 7,462,863.00 美元。出售完成後，該內部人士現在直接持有該公司 169,803 股，價值約為 4,712,033.25 美元。這代表其持股減少了 61.30%。該出售在提交給證券交易委員會的文件中披露，文件可通過 SEC 網站訪問。此外，首席執行官 Andrew Dudum 於 1 月 16 日以交易方式出售了 36,460 股該公司的股票。該股票的平均售價為 27.09 美元，總價值為 987,701.40 美元。交易完成後，首席執行官現在持有該公司 27,918 股，價值約為 756,298.62 美元。這代表其持股減少了 56.63%。該出售的披露信息可以在此找到。內部人士在過去 90 天內出售了 890,592 股公司股票，價值 31,677,291 美元。公司內部人士持有該公司股票的 17.71%。</p>
<h2>Hims</h2>
<p>&amp; Hers Health 的機構交易</p>
<p>幾家大型投資者最近購買和出售了 HIMS 的股票。Crewe Advisors LLC 在第四季度購買了 Hims
&amp; Hers Health 的新頭寸，價值 28,000 美元。Raleigh Capital Management Inc. 在第四季度將其在 Hims
&amp; Hers Health 的持股增加了 1,100.0%。Raleigh Capital Management Inc. 現在擁有該公司 1,200 股股票，價值 29,000 美元，此前在上個季度又購買了 1,100 股。Blume Capital Management Inc. 在第四季度將其在 Hims
&amp; Hers Health 的持股增加了 100.0%。Blume Capital Management Inc. 現在擁有該公司 1,200 股股票，價值 29,000 美元，此前在上個季度又購買了 600 股。Smartleaf Asset Management LLC 在第四季度將其在 Hims
&amp; Hers Health 的持股增加了 4,415.6%。Smartleaf Asset Management LLC 現在擁有該公司 1,445 股股票，價值 36,000 美元，此前在上個季度又收購了 1,413 股。最後，Summit Securities Group LLC 在第四季度購買了 Hims
&amp; Hers Health 的新股份，價值約 38,000 美元。機構投資者和對沖基金持有該公司 63.52% 的股票。</p>
<h2>關於 Hims</h2>
<p>&amp; Hers Health</p>
<p>(獲取免費報告)</p>
<p>Hims
&amp; Hers Health, Inc. 運營一個遠程醫療諮詢平台。它將消費者與醫療專業人員連接，使他們能夠獲得心理健康、性健康、皮膚病和初級護理的醫療服務。該公司成立於 2017 年，總部位於加利福尼亞州舊金山。</p>
<h2>精選文章</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Hims
&amp; Hers Health</li>
<li>基礎材料股票投資</li>
<li>Joby Aviation 股票：維珍大西洋交易信號巨大潛力</li>
<li>恒生指數是什麼？</li>
<li>Kohl’s 發佈了另一個 “廚房水槽” 季度，但新 CEO 有計劃</li>
<li>有哪些值得購買的大型股票？</li>
<li>西南航空可能會從這裏三倍增長——這是方法</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhJTVM?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhJTVM"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前經過 MarketBeat 編輯團隊的審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 Hims &amp; Hers Health 嗎？</h2>
<p>在考慮 Hims &amp; Hers Health 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Hims &amp; Hers Health 並不在名單上。</p>
<p>雖然 Hims &amp; Hers Health 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

HIMS

<p>美國銀行將 Hims & Hers Health（紐約證券交易所代碼：HIMS）的目標股價從 21.00 美元上調至 22.00 美元，維持 “表現不佳” 的評級。這個新目標暗示當前價格可能下跌 36.56%。其他分析師的觀點各異，目標股價範圍從 24.00 美元到 68.00 美元不等。Hims & Hers Health 的股票開盤價為 34.68 美元，市值為 77 億美元，市盈率為 78.82。該公司報告上個季度每股收益為 0.11 美元，超出預期</p>

<p>Hims &amp; Hers Health (NYSE:HIMS - Get Free Report) had its price target raised by stock analysts at Bank of America from $21.00 to $22.00 in a research note issued to investors on Tuesday,Benzinga reports. The firm currently has an &#34;underperform&#34; rating on the stock. Bank of America's price target would indicate a potential downside of 36.56% from the company's current price.</p>
<div class="lb-trans"><p>Hims
&amp; Hers Health (NYSE:HIMS - 獲取免費報告) 在週二發佈給投資者的研究報告中，銀行美林的股票分析師將其目標價格從 21.00 美元上調至 22.00 美元。該公司目前對該股票的評級為 “表現不佳”。銀行美林的目標價格意味着該公司當前價格可能下跌 36.56%。</p>
</div><p>Get <strong>Hims &amp; Hers Health</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Hims
&amp; Hers Health</strong> 的提醒：</p>
</div><ul>
<li>Is Viking Therapeutics the Next Blockbuster GLP-1 Stock?</li>
</ul>
<div class="lb-trans"><ul>
<li>Viking Therapeutics 是下一個熱門的 GLP-1 股票嗎？</li>
</ul>
</div><p>A number of other equities research analysts also recently issued reports on HIMS. Truist Financial lifted their price target on shares of Hims &amp; Hers Health from $24.00 to $39.00 and gave the company a &#34;hold&#34; rating in a research report on Wednesday, February 26th. Leerink Partners increased their price objective on Hims &amp; Hers Health from $24.00 to $40.00 and gave the company a &#34;market perform&#34; rating in a research note on Tuesday, February 25th. Needham &amp; Company LLC lifted their price objective on Hims &amp; Hers Health from $31.00 to $61.00 and gave the stock a &#34;buy&#34; rating in a research report on Tuesday, February 25th. Citigroup restated a &#34;sell&#34; rating and issued a $27.00 target price on shares of Hims &amp; Hers Health in a report on Thursday, March 6th. Finally, Canaccord Genuity Group lifted their price target on shares of Hims &amp; Hers Health from $38.00 to $68.00 and gave the stock a &#34;buy&#34; rating in a report on Wednesday, February 19th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of &#34;Hold&#34; and an average price target of $37.31.</p>
<div class="lb-trans"><p>其他一些股票研究分析師最近也對 HIMS 發佈了報告。Truist Financial 將 Hims
&amp; Hers Health 的目標價格從 24.00 美元上調至 39.00 美元，並在 2 月 26 日的研究報告中給予該公司 “持有” 評級。Leerink Partners 將 Hims
&amp; Hers Health 的目標價格從 24.00 美元上調至 40.00 美元，並在 2 月 25 日的研究報告中給予該公司 “市場表現” 評級。Needham
&amp; Company LLC 將 Hims
&amp; Hers Health 的目標價格從 31.00 美元上調至 61.00 美元，並在 2 月 25 日的研究報告中給予該股票 “買入” 評級。花旗集團在 3 月 6 日的報告中重申了 “賣出” 評級，並對 Hims
&amp; Hers Health 的股票設定了 27.00 美元的目標價格。最後，Canaccord Genuity Group 將 Hims
&amp; Hers Health 的目標價格從 38.00 美元上調至 68.00 美元，並在 2 月 19 日的報告中給予該股票 “買入” 評級。兩位股票研究分析師對該股票給予了賣出評級，七位給予了持有評級，六位給予了買入評級。根據 MarketBeat 的數據，該股票的共識評級為 “持有”，平均目標價格為 37.31 美元。</p>
</div><p><strong>View Our Latest Stock Report on Hims &amp; Hers Health</strong></p>
<div class="lb-trans"><p>** 查看我們最新的 Hims
&amp; Hers Health 股票報告 **</p>
</div><h2>Hims &amp; Hers Health Stock Up 4.6 %</h2>
<div class="lb-trans"><h2>Hims</h2>
<p>&amp; Hers Health 股票上漲 4.6%</p>
</div><ul>
<li>Despite Challenges Novo Nordisk Plans to Crush GLP-1 Competitors</li>
</ul>
<div class="lb-trans"><ul>
<li>儘管面臨挑戰，諾和諾德計劃擊敗 GLP-1 競爭對手</li>
</ul>
</div><p>HIMS opened at $34.68 on Tuesday. The business has a 50 day moving average price of $38.64 and a two-hundred day moving average price of $28.37. Hims &amp; Hers Health has a 52 week low of $11.20 and a 52 week high of $72.98. The company has a market cap of $7.70 billion, a PE ratio of 78.82 and a beta of 1.37.</p>
<div class="lb-trans"><p>HIMS 週二開盤價為 34.68 美元。該公司的 50 日移動平均價格為 38.64 美元，200 日移動平均價格為 28.37 美元。Hims
&amp; Hers Health 的 52 周低點為 11.20 美元，52 周高點為 72.98 美元。該公司的市值為 77 億美元，市盈率為 78.82，貝塔值為 1.37。</p>
</div><p>Hims &amp; Hers Health (NYSE:HIMS - Get Free Report) last issued its quarterly earnings results on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.09 by $0.02. Hims &amp; Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The business had revenue of $481.14 million for the quarter, compared to analyst estimates of $494.56 million. As a group, sell-side analysts expect that Hims &amp; Hers Health will post 0.29 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Hims
&amp; Hers Health (NYSE:HIMS - 獲取免費報告) 最近在 2 月 24 日發佈了季度財報。該公司報告每股收益（EPS）為 0.11 美元，超出分析師共識預期的 0.09 美元，超出幅度為 0.02 美元。Hims
&amp; Hers Health 的淨利潤率為 8.19%，股本回報率為 10.97%。該公司本季度的收入為 4.8114 億美元，而分析師預期為 4.9456 億美元。整體來看，賣方分析師預計 Hims
&amp; Hers Health 本財年的每股收益將為 0.29 美元。</p>
</div><h2>Insider Transactions at Hims &amp; Hers Health</h2>
<div class="lb-trans"><h2>Hims</h2>
<p>&amp; Hers Health 的內部交易</p>
</div><ul>
<li>MarketBeat Week in Review – 03/03 - 03/07</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 週迴顧 – 03/03 - 03/07</li>
</ul>
</div><p>In related news, insider Soleil Boughton sold 268,932 shares of the stock in a transaction on Monday, January 6th. The stock was sold at an average price of $27.75, for a total value of $7,462,863.00. Following the completion of the sale, the insider now directly owns 169,803 shares in the company, valued at approximately $4,712,033.25. This represents a 61.30 % decrease in their position. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through the SEC website. Also, CEO Andrew Dudum sold 36,460 shares of the business's stock in a transaction dated Thursday, January 16th. The stock was sold at an average price of $27.09, for a total value of $987,701.40. Following the transaction, the chief executive officer now owns 27,918 shares in the company, valued at approximately $756,298.62. This represents a 56.63 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 890,592 shares of company stock valued at $31,677,291 over the last 90 days. Corporate insiders own 17.71% of the company's stock.</p>
<div class="lb-trans"><p>在相關消息中，內部人士 Soleil Boughton 於 1 月 6 日以交易方式出售了 268,932 股該股票。該股票的平均售價為 27.75 美元，總價值為 7,462,863.00 美元。出售完成後，該內部人士現在直接持有該公司 169,803 股，價值約為 4,712,033.25 美元。這代表其持股減少了 61.30%。該出售在提交給證券交易委員會的文件中披露，文件可通過 SEC 網站訪問。此外，首席執行官 Andrew Dudum 於 1 月 16 日以交易方式出售了 36,460 股該公司的股票。該股票的平均售價為 27.09 美元，總價值為 987,701.40 美元。交易完成後，首席執行官現在持有該公司 27,918 股，價值約為 756,298.62 美元。這代表其持股減少了 56.63%。該出售的披露信息可以在此找到。內部人士在過去 90 天內出售了 890,592 股公司股票，價值 31,677,291 美元。公司內部人士持有該公司股票的 17.71%。</p>
</div><h2>Institutional Trading of Hims &amp; Hers Health</h2>
<div class="lb-trans"><h2>Hims</h2>
<p>&amp; Hers Health 的機構交易</p>
</div><p>Several large investors have recently bought and sold shares of HIMS. Crewe Advisors LLC purchased a new position in shares of Hims &amp; Hers Health in the fourth quarter valued at $28,000. Raleigh Capital Management Inc. lifted its holdings in Hims &amp; Hers Health by 1,100.0% in the 4th quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after buying an additional 1,100 shares in the last quarter. Blume Capital Management Inc. boosted its position in Hims &amp; Hers Health by 100.0% in the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock valued at $29,000 after buying an additional 600 shares during the last quarter. Smartleaf Asset Management LLC grew its stake in shares of Hims &amp; Hers Health by 4,415.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company's stock valued at $36,000 after acquiring an additional 1,413 shares in the last quarter. Finally, Summit Securities Group LLC purchased a new stake in shares of Hims &amp; Hers Health during the fourth quarter worth about $38,000. Institutional investors and hedge funds own 63.52% of the company's stock.</p>
<div class="lb-trans"><p>幾家大型投資者最近購買和出售了 HIMS 的股票。Crewe Advisors LLC 在第四季度購買了 Hims
&amp; Hers Health 的新頭寸，價值 28,000 美元。Raleigh Capital Management Inc. 在第四季度將其在 Hims
&amp; Hers Health 的持股增加了 1,100.0%。Raleigh Capital Management Inc. 現在擁有該公司 1,200 股股票，價值 29,000 美元，此前在上個季度又購買了 1,100 股。Blume Capital Management Inc. 在第四季度將其在 Hims
&amp; Hers Health 的持股增加了 100.0%。Blume Capital Management Inc. 現在擁有該公司 1,200 股股票，價值 29,000 美元，此前在上個季度又購買了 600 股。Smartleaf Asset Management LLC 在第四季度將其在 Hims
&amp; Hers Health 的持股增加了 4,415.6%。Smartleaf Asset Management LLC 現在擁有該公司 1,445 股股票，價值 36,000 美元，此前在上個季度又收購了 1,413 股。最後，Summit Securities Group LLC 在第四季度購買了 Hims
&amp; Hers Health 的新股份，價值約 38,000 美元。機構投資者和對沖基金持有該公司 63.52% 的股票。</p>
</div><h2>About Hims &amp; Hers Health</h2>
<div class="lb-trans"><h2>關於 Hims</h2>
<p>&amp; Hers Health</p>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>Hims &amp; Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.</p>
<div class="lb-trans"><p>Hims
&amp; Hers Health, Inc. 運營一個遠程醫療諮詢平台。它將消費者與醫療專業人員連接，使他們能夠獲得心理健康、性健康、皮膚病和初級護理的醫療服務。該公司成立於 2017 年，總部位於加利福尼亞州舊金山。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than Hims &amp; Hers Health</li>
<li>Basic Materials Stocks Investing</li>
<li>Joby Aviation Stock: Virgin Atlantic Deal Signals Big Potential</li>
<li>What is the Hang Seng index?</li>
<li>Kohl’s Posts Another Kitchen Sink Quarter, But New CEO Has a Plan</li>
<li>What Are Some of the Best Large-Cap Stocks to Buy?</li>
<li>Southwest Airlines Could Triple From Here—Here's How</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Hims
&amp; Hers Health</li>
<li>基礎材料股票投資</li>
<li>Joby Aviation 股票：維珍大西洋交易信號巨大潛力</li>
<li>恒生指數是什麼？</li>
<li>Kohl’s 發佈了另一個 “廚房水槽” 季度，但新 CEO 有計劃</li>
<li>有哪些值得購買的大型股票？</li>
<li>西南航空可能會從這裏三倍增長——這是方法</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhJTVM" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NYSE&amp;Symbol=HIMS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前經過 MarketBeat 編輯團隊的審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Hims &amp; Hers Health Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Hims &amp; Hers Health 嗎？</h2>
</div><p>Before you consider Hims &amp; Hers Health, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Hims &amp; Hers Health 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hims &amp; Hers Health wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Hims &amp; Hers Health 並不在名單上。</p>
</div><p>While Hims &amp; Hers Health currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Hims &amp; Hers Health 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Hims & Hers Health（紐約證券交易所代碼：HIMS）在美國銀行被設定了新的 22.00 美元目標價